{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:44:03Z","timestamp":1767152643065,"version":"build-2238731810"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1038\/nrclinonc.2009.161","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T05:49:14Z","timestamp":1256708954000},"page":"622-624","source":"Crossref","is-referenced-by-count":3,"title":["The case against rituximab maintenance"],"prefix":"10.1038","volume":"6","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrclinonc2009161_CR1","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth, J. D.  et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746\u20131751 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161_CR2","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini, M.  et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with weekly \u00d74 schedule. Blood 103, 4416\u20134423 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc2009161_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster, H.  et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607\u20131614 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161_CR4","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner, R.  et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003\u20134008 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009161_CR5","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers, M. H.  et al. Rituximab maintenance improves clinical outcome of relapsed\/refractory follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108, 3295\u20133301 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009161_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V112.11.309.309","volume":"112","author":"MHJ Van Oers","year":"2008","unstructured":"Van Oers, M. H. J.  et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract 836]. Blood 112, 309\u2013310 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009161_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jnci\/djn478","volume":"101","author":"L Vidal","year":"2009","unstructured":"Vidal, L.  et al. Rituximab maintenance for the treatment of patients with follicular lymphma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248\u2013255 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2009161_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth, J. D.  et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088\u20131095 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161_CR9","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann, T. M.  et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 3121\u20133127 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009161_CR10","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser, F.  et al. Phase III trial of consolidation therapy with 90Y-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26, 5156\u20135164 (2008).","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/nrclinonc.2009.190","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.161","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:02:36Z","timestamp":1684454556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["BFnrclinonc2009161"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.161","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}